X
<

GlaxoSmithKline’s Latest Developments and Valuation

PART:
1 2 3 4 5 6 7 8 9
Part 8
GlaxoSmithKline’s Latest Developments and Valuation PART 8 OF 9

Performance of GlaxoSmithKline’s Consumer Healthcare Segment

Consumer healthcare

GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio. The segment’s revenues were nearly flat at 1.9 billion pounds in 2Q17 compared to 2Q16.

Performance of GlaxoSmithKline’s Consumer Healthcare Segment

Interested in GSK? Don't miss the next report.

Receive e-mail alerts for new research on GSK

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart shows revenues for the Consumer Healthcare segment over the last few quarters. Pain relief drugs and oral health products were the growth drivers for this segment, while allergy products impacted growth.

New products

New products added to the Consumer Healthcare segment in the last three years reported a rise in revenues in 2Q17, contributing more than 12.0% of total revenues for the segment. New products launched in 2Q17 include Flonase OTC (over the counter), Pronamel Strong & Bright, and Sensodyne Rapid.

Geographical performance

The US markets reported an 8.0% fall in revenues at constant exchange rates to 430.0 million pounds in 2Q17 compared to 2Q16, driven by weaker sales of allergy products.

The European markets reported a 7.0% rise in revenues at constant exchange rates to 579.0 million pounds in 2Q17 compared to 2Q16, driven by an increase in sales of Sensodyne oral health products and Voltaren, a pain relief product.

International revenues reported nearly flat revenues to 843.0 million pounds in 2Q17 compared to 2Q16 due to weak sales in major categories.

The Vanguard FTSE Europe ETF (VGK) has 0.90% of its total assets in GlaxoSmithKline. VGK also holds 1.9% in Novartis (NVS), 0.70% in Novo Nordisk (NVO), and 0.70% in AstraZeneca (AZN).

X

Please select a profession that best describes you: